Alkermes (ALKS) Total Current Liabilities (2011 - 2026)
Alkermes (ALKS) reported Total Current Liabilities of $599.5 million for Q1 2026, up 35.1% year-over-year from $443.7 million in Q1 2025, and up 10.32% quarter-over-quarter from $543.4 million in Q4 2025.
Alkermes (ALKS) Total Current Liabilities (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Total Current Liabilities data on file, last reported at $599.5 million in Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $599.5 million, up 35.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $599.5 million (up 35.1% YoY), and the FY2025 annual result was $543.4 million, up 16.82% from the prior year.
- Total Current Liabilities grew to $599.5 million in Q1 2026 per ALKS's latest filing, from $543.4 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $599.5 million in Q1 2026 and troughed at $438.5 million in Q2 2022.
- A 5-year average of $490.1 million and a median of $487.2 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Current Liabilities slipped 10.58% in 2024, then surged 35.1% in 2026.
- A 5-year view of Total Current Liabilities shows it stood at $497.7 million in 2022, then gained by 4.52% to $520.2 million in 2023, then decreased by 10.58% to $465.2 million in 2024, then rose by 16.82% to $543.4 million in 2025, then climbed by 10.32% to $599.5 million in 2026.
- Business Quant data shows ALKS's Total Current Liabilities at $599.5 million in Q1 2026, $543.4 million in Q4 2025, and $474.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 13.53 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 2.05 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 831.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 1.66 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 599.50 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 333.17 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 618.78 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 149.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 599.50 Mn |
| Dec 31, 2025 | 543.44 Mn |
| Sep 30, 2025 | 474.36 Mn |
| Jun 30, 2025 | 505.96 Mn |
| Mar 31, 2025 | 443.73 Mn |
| Dec 31, 2024 | 465.20 Mn |
| Sep 30, 2024 | 453.71 Mn |
| Jun 30, 2024 | 515.55 Mn |
| Mar 31, 2024 | 458.98 Mn |
| Dec 31, 2023 | 520.22 Mn |
| Sep 30, 2023 | 503.11 Mn |
| Jun 30, 2023 | 487.19 Mn |
| Mar 31, 2023 | 492.91 Mn |
| Dec 31, 2022 | 497.74 Mn |
| Sep 30, 2022 | 469.56 Mn |
| Jun 30, 2022 | 438.52 Mn |
| Mar 31, 2022 | 462.36 Mn |
| Dec 31, 2021 | 471.29 Mn |
| Sep 30, 2021 | 452.98 Mn |
| Jun 30, 2021 | 383.44 Mn |